Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Wancjer Meid, Benjamin"'
Autor:
Wancjer Meid, Benjamin, Molano Triviño, Alejandra Patricia, Perez-Fernandez, Oscar-Mauricio, Cantillo Manotas, Wainer
Publikováno v:
Eckardt K-U, Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. The Lancet.382(9887):158-69.
James MT, Tonelli M, for the Alberta Kidney Disease N. Financial Aspects of Renal Replacement Therapy in Acute Kidney Injury. Seminars in Dialysis. 2011;24(2):215-9.
De Smedt DM, Elseviers MM, Lins RL, Annemans L. Economic evaluation of different treatment modalities in acute kidney injury. Nephrology Dialysis Transplantation. 2012;27(11):4095-101.
Kim IB, Fealy N, Baldwin I, Bellomo R. Premature Circuit Clotting due to Likely Mechanical Failure during Continuous Renal Replacement Therapy. Blood Purification. 2010;30(2):79-83.
Cutts MWJ, Thomas AN, Kishen R. Transfusion requirements during continuous veno-venous haemofiltration: – the importance of filter life. Intensive Care Medicine. 2000;26(11):1694-7.
Parienti J-J, Mégarbane B, Fischer M-O, Lautrette A, Gazui N, Marin N, et al. Catheter dysfunction and dialysis performance according to vascular access among 736 critically ill adults requiring renal replacement therapy: A randomized controlled study. Critical Care Medicine. 2010;38(4).
Krouzecky A, Chvojka J, Sykora R, Radej J, Karvunidis T, Novak I, et al. Regional cooling of the extracorporeal blood circuit: a novel anticoagulation approach for renal replacement therapy? Intensive Care Medicine. 2009;35(2):364-70.
Bagshaw S, Davenport A. Cooling and reduced risk of clotting within the extracorporeal continuous renal replacement circuit. Intensive Care Medicine. 2009;35(2):195-7.
Baldwin I, Bellomo R, Koch B. Blood flow reductions during continuous renal replacement therapy and circuit life. Intensive Care Medicine. 2004;30(11):2074-9.
Baldwin I, Tan HK, Bridge N, Bellomo R. POSSIBLE STRATEGIES TO PROLONG CIRCUIT LIFE DURING HEMOFILTRATION: THREE CONTROLLED STUDIES. Renal Failure. 2002;24(6):839.
Nagarik Amit P SSS, Adikey Gopal Kishan, Raman Anuradha. Comparative study of anticoagulation versus saline flushes in continuous renal replacement therapy. Saudi J Kidney Dis Transpl. 2010;21(10):478-83.
Scribner BH CJ, Buri R, Quinton W. The technique of continuous hemodialysis. Trans Am Soc Artif Intern Organs. 1960;6:88-103.
Kidney D. Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter., Suppl.2012(2):1-138.
Li PKT, Burdmann EA, Mehta RL, for the World Kidney Day Steering Committee. Acute Kidney Injury: Global Health Alert. Transplantation. 2013;95(5):653-7.
Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, et al. Acute kidney injury: an increasing global concern. The Lancet.382(9887):170-9.
Schissler MM, Zaidi S, Kumar H, Deo D, Brier ME, McLeish KR. Characteristics and outcomes in community-acquired versus hospital-acquired acute kidney injury. Nephrology. 2013;18(3):183-7.
Finlay S, Bray B, Lewington AJ, Hunter-Rowe CT, Banerjee A, Atkinson JM, et al. Identification of risk factors associated with acute kidney injury in patients admitted to acute medical units. Clinical Medicine. 2013;13(3):238-88.
Wehbe E, Brock R, Budev M, Xu M, Demirjian S, Schreiber Jr MJ, et al. Short-term and long-term outcomes of acute kidney injury after lung transplantation. The Journal of Heart and Lung Transplantation. 2012;31(3):244-51.
Choi JS, Kim YA, Kim MJ, Kang YU, Kim CS, Bae EH, et al. Relation Between Transient or Persistent Acute Kidney Injury and Long-Term Mortality in Patients With Myocardial Infarction. The American Journal of Cardiology. 2013;112(1):41-5.
Schneider A, Bellomo R, Bagshaw S, Glassford N, Lo S, Jun M, et al. Choice of renal replacement therapy modality and dialysis dependence after acute kidney 47 injury: a systematic review and meta-analysis. Intensive Care Medicine. 2013;39(6):987-97.
Sanchez J, Maynar J, Herrera M. Terapias continuas de depuración extrarenal (TCDE). In: Poch E, Liaño F, Gaínza FJ, editors. MANEJO DE LA DISFUNCION AGUDA DEL RIÑON, del paciente critico en la practica clinica. 1. 1 ed. Madrid: Ergon; 2011. p. 69-86.
Davenport A, Neng K, Hertel J, Caruana R. anticoagulación. In: Daugirdas JT, editor. MANUAL DE DIALISIS. 1. 4 ed. Barcelona (España): Wolters Kluwer Health España S.A., Lippincott Williams & Wilkins; 2008 Copyrigth 2007 edicion en ingles. p. 203-15.
Lucchi L, Ligabue G, Marietta M, Delnevo A, Malagoli M, Perrone S, et al. Activation of Coagulation During Hemodialysis: Effect of Blood Lines Alone and Whole Extracorporeal Circuit. Artificial Organs. 2006;30(2):106-10.
Rebecca AC, Helen M, Ian JM, Samuel JM, Mervyn S. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney International. 1999;55(4):1568-74.
Gaínza FJ, Urbizu JM. Accesos vasculares, membranas y anticoagulacion extracorporea para tecnicas continuas o intermitentes en UCI. In: Poch E, Liaño F, Gaínza FJ, editors. MANEJO DE LA DISFUNCION AGUDA DEL RIÑON, del paciente critico en la practica clinica. 1. 1 ed. Madrid: Ergon; 2011. p. 55-68.
Oudemans-van Straaten HM. Citrate Anticoagulation for Continuous Renal Replacement Therapy in the Critically Ill. Blood Purification. 2010;29(2):191-6.
del Castillo J, Lopez-Herce J, Cidoncha E, Urbano J, Mencia S, Santiago M, et al. Circuit life span in critically ill children on continuous renal replacement treatment: a prospective observational evaluation study. Critical Care. 2008;12(4):R93.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
James MT, Tonelli M, for the Alberta Kidney Disease N. Financial Aspects of Renal Replacement Therapy in Acute Kidney Injury. Seminars in Dialysis. 2011;24(2):215-9.
De Smedt DM, Elseviers MM, Lins RL, Annemans L. Economic evaluation of different treatment modalities in acute kidney injury. Nephrology Dialysis Transplantation. 2012;27(11):4095-101.
Kim IB, Fealy N, Baldwin I, Bellomo R. Premature Circuit Clotting due to Likely Mechanical Failure during Continuous Renal Replacement Therapy. Blood Purification. 2010;30(2):79-83.
Cutts MWJ, Thomas AN, Kishen R. Transfusion requirements during continuous veno-venous haemofiltration: – the importance of filter life. Intensive Care Medicine. 2000;26(11):1694-7.
Parienti J-J, Mégarbane B, Fischer M-O, Lautrette A, Gazui N, Marin N, et al. Catheter dysfunction and dialysis performance according to vascular access among 736 critically ill adults requiring renal replacement therapy: A randomized controlled study. Critical Care Medicine. 2010;38(4).
Krouzecky A, Chvojka J, Sykora R, Radej J, Karvunidis T, Novak I, et al. Regional cooling of the extracorporeal blood circuit: a novel anticoagulation approach for renal replacement therapy? Intensive Care Medicine. 2009;35(2):364-70.
Bagshaw S, Davenport A. Cooling and reduced risk of clotting within the extracorporeal continuous renal replacement circuit. Intensive Care Medicine. 2009;35(2):195-7.
Baldwin I, Bellomo R, Koch B. Blood flow reductions during continuous renal replacement therapy and circuit life. Intensive Care Medicine. 2004;30(11):2074-9.
Baldwin I, Tan HK, Bridge N, Bellomo R. POSSIBLE STRATEGIES TO PROLONG CIRCUIT LIFE DURING HEMOFILTRATION: THREE CONTROLLED STUDIES. Renal Failure. 2002;24(6):839.
Nagarik Amit P SSS, Adikey Gopal Kishan, Raman Anuradha. Comparative study of anticoagulation versus saline flushes in continuous renal replacement therapy. Saudi J Kidney Dis Transpl. 2010;21(10):478-83.
Scribner BH CJ, Buri R, Quinton W. The technique of continuous hemodialysis. Trans Am Soc Artif Intern Organs. 1960;6:88-103.
Kidney D. Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter., Suppl.2012(2):1-138.
Li PKT, Burdmann EA, Mehta RL, for the World Kidney Day Steering Committee. Acute Kidney Injury: Global Health Alert. Transplantation. 2013;95(5):653-7.
Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, et al. Acute kidney injury: an increasing global concern. The Lancet.382(9887):170-9.
Schissler MM, Zaidi S, Kumar H, Deo D, Brier ME, McLeish KR. Characteristics and outcomes in community-acquired versus hospital-acquired acute kidney injury. Nephrology. 2013;18(3):183-7.
Finlay S, Bray B, Lewington AJ, Hunter-Rowe CT, Banerjee A, Atkinson JM, et al. Identification of risk factors associated with acute kidney injury in patients admitted to acute medical units. Clinical Medicine. 2013;13(3):238-88.
Wehbe E, Brock R, Budev M, Xu M, Demirjian S, Schreiber Jr MJ, et al. Short-term and long-term outcomes of acute kidney injury after lung transplantation. The Journal of Heart and Lung Transplantation. 2012;31(3):244-51.
Choi JS, Kim YA, Kim MJ, Kang YU, Kim CS, Bae EH, et al. Relation Between Transient or Persistent Acute Kidney Injury and Long-Term Mortality in Patients With Myocardial Infarction. The American Journal of Cardiology. 2013;112(1):41-5.
Schneider A, Bellomo R, Bagshaw S, Glassford N, Lo S, Jun M, et al. Choice of renal replacement therapy modality and dialysis dependence after acute kidney 47 injury: a systematic review and meta-analysis. Intensive Care Medicine. 2013;39(6):987-97.
Sanchez J, Maynar J, Herrera M. Terapias continuas de depuración extrarenal (TCDE). In: Poch E, Liaño F, Gaínza FJ, editors. MANEJO DE LA DISFUNCION AGUDA DEL RIÑON, del paciente critico en la practica clinica. 1. 1 ed. Madrid: Ergon; 2011. p. 69-86.
Davenport A, Neng K, Hertel J, Caruana R. anticoagulación. In: Daugirdas JT, editor. MANUAL DE DIALISIS. 1. 4 ed. Barcelona (España): Wolters Kluwer Health España S.A., Lippincott Williams & Wilkins; 2008 Copyrigth 2007 edicion en ingles. p. 203-15.
Lucchi L, Ligabue G, Marietta M, Delnevo A, Malagoli M, Perrone S, et al. Activation of Coagulation During Hemodialysis: Effect of Blood Lines Alone and Whole Extracorporeal Circuit. Artificial Organs. 2006;30(2):106-10.
Rebecca AC, Helen M, Ian JM, Samuel JM, Mervyn S. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney International. 1999;55(4):1568-74.
Gaínza FJ, Urbizu JM. Accesos vasculares, membranas y anticoagulacion extracorporea para tecnicas continuas o intermitentes en UCI. In: Poch E, Liaño F, Gaínza FJ, editors. MANEJO DE LA DISFUNCION AGUDA DEL RIÑON, del paciente critico en la practica clinica. 1. 1 ed. Madrid: Ergon; 2011. p. 55-68.
Oudemans-van Straaten HM. Citrate Anticoagulation for Continuous Renal Replacement Therapy in the Critically Ill. Blood Purification. 2010;29(2):191-6.
del Castillo J, Lopez-Herce J, Cidoncha E, Urbano J, Mencia S, Santiago M, et al. Circuit life span in critically ill children on continuous renal replacement treatment: a prospective observational evaluation study. Critical Care. 2008;12(4):R93.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: las terapias continuas de reemplazo renal son una importante medida a utilizar en los pacientes con lesión renal aguda que ingresan a la unidad de cuidado intensivo, la pérdida temprana del circuito por coagulación del mismo es una
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00182798518bc7aaf63e212e758ed967
http://repository.urosario.edu.co/handle/10336/10602
http://repository.urosario.edu.co/handle/10336/10602
Autor:
Wancjer Meid, Benjamin, Rincón, Ximena, Romero, Íngrid, Santamaría, Germán, Dalmau, Ernesto, Andrade, Rafael, Bohórquez, Claudio, Díaz, Andrés, Muñoz, Jesús
Publikováno v:
Revista Ciencias de la Salud; Vol. 1, núm. 2 (2003)
Revista Ciencias de la Salud; Vol. 1, No. 2 (2003)
Revista Ciencias de la Salud; v. 1, n. 2 (2003)
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Revista Ciencias de la Salud; Vol. 1, No. 2 (2003)
Revista Ciencias de la Salud; v. 1, n. 2 (2003)
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Objetivos: determinar los cambios anatómicos del ejercicio en el envejecimiento renal. Metodología: estudio longitudinal experimental durante 54 semanas. Se tomaron 120 ratones machos cepa Suizo, los cuales según su actividad se dividieron en 3 gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3056::325f7668387c424060922c3003b1e957
http://repository.urosario.edu.co/handle/10336/7541
http://repository.urosario.edu.co/handle/10336/7541
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Galván Marín, Ángel Rolando
Publikováno v:
Thakur S, Rao SN. Effects of Reduced Dialysis Fluid Flow in Hemodialysis. Igarss 2014. 2014;(1):1-5. doi:10.1007/s13398-014-0173-7.2.
World Kidney Day 2015; http://www.worldkidneyday.org/faqs/chronic-kidney-disease/.
Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. Jul 20 2013;382(9888):260-272.
Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. Dec 2011;80(12):1258-1270.
Connor A, Lillywhite R, Cooke MW. The carbon footprints of home and in-center maintenance hemodialysis in the United Kingdom. Hemodial Int. 2011 Jan;15(1):39-51. doi: 10.1111/j.1542-4758.2010.00523. x. Epub 2011 Jan 14
Daugirdas JT. Bases fisiológicas y modelo cinético de la urea. Manual de diálisis. 4ta ed. Madrid: Lippincott and Wilkins; 2007.
Nissenson AR, Fine RN. Modelo cinético de la urea como guía terapéutica de hemodiálisis en adultos. Manual de diálisis. 4ta ed. Madrid: Elsevier Masson; 2008.
Ward AR, Idoux WJ, Ouseph R, Depner T, Golper T. Dialysate flow rate and delivered Kt/V urea fordialyzers with enhanced dialysate flow distribution. Clinical J SocNeph 2011; 6: 2235-9.
Ouseph R, Ward AR. Increasing dialysate flow rate increases dialyzer urea mass transfer-area coefficients during clinical use. Am J Kidney Dis 2001; 37 (2): 316-20.
Bhimani JP, Ouseph R, Ward RA. Effect of increasing dialysate flow rate on diffusive mass transfer of urea, phosphate and β2-microglobulin during clinical haemodialysis. Nephrol Dial Transplant 2010; 25 (12): 3990-5.
Leypoldt J, Craig D. Kamerath, Janice F. Gilson, And Goetz Friederichs Dialyzer Clearances and Mass Transfer-Area Coefficients for Small Solutes at Low Dialysate Flow Rates, ASAIO Journal 2007 DOI: 10.1097/01.mat.0000245525.83936.79
Asar AT. Increasing dialysate flow rate increases dyalizer urea clearence and dialysis efficiency: an in vivo study. Saudi J Kidney Dis Transpl 2009; 6 (20): 1023-9.
Alayoud A, Benyahia M, Montassir D, Hamzi A, Zajjari Y, Bahadi A, El Kabbaj D et al. A model to predict optimal dialysate flow. Therap Apheresis Dial 2012; 16 (2): 152-8.
Ducuara D, Molano A, Yunez A, Wancjer B, Effect of flow adjustment dialysate (Qd) hemodialysis on effectiveness of underweight patients, Revista Ciencias de la Salud 11(2):173-183 · August 2013
Ahrenholz P, Roland E. Winkler, Diego Zendeh-Zartochti The role of the dialysate flow rate in haemodialysisBioArt Products GmbH Rostock, 2: Praxis verbundDialyse und Apherese Rostock, September 2013 DOI: 10.5772/58878
Yamamoto K, Matsukawa H, Yakushiji T, Technical Evaluation of Dialysate Flow in a Newly Designed Dialyzer, ASAIO Journal 2007; 53:36-40.
Agar JWM, Simmonds RE, Knight R, Somerville CA. Using water wisely: New, affordable, and essential water conservation practices for facility and home hemodialysis. Hemodial Int. 2009;13(1):32-37. doi:10.1111/j.1542-4758.2009.00332.x.
World Health Organization. Guidelines for drinking-water quality: recommendations. Vol. 1. World Health Organization, 2004.
Agar JWM. Green Dialysis: The Environmental Challenges A head. Semin Dial. 2015;28(2):186-192. doi:10.1111/sdi.12324.
Sanabria M, Moreno J, Vesga J, Astudillo K, Bunch A, et al. Mortalidad observada versus esperada en una red de unidades de diálisis en Colombia. Acta Médica Colombiana 2017;42:106-111.
Otero GA, De Francisco A, Gayoso P, García F. Prevalencia de la insuficiencia renal crónica en España: Resultados del estudio EPIRCE. Nefrología. 2010;30(01):78-86.
Wagner M, et al. Predicting Mortality in Incident Dialysis Patients: An Analysis of the United Kingdom Renal Registry. Am J Kidney Dis. 2011;57(6):894-902.
Pérez-García, Rafael, et al. "Estudio epidemiológico de 7316 pacientes en hemodiálisis tratados en las clínicas Fresenius Medical Care de España, con los datos obtenidos mediante la base de datos EuCliD®: resultados de los años 2009-2010." Nefrología (Madrid) 32.6 (2012): 743-753.
Kashiwagi, Tetsuya, et al. "Effects of reduced dialysis fluid flow in hemodialysis." Journal of Nippon Medical School 80.2 (2013): 119-130.
Brattich M. Morbidity and mortality in patients on dialysis: the impact of hemoglobin levels. Nephrol Nursing J. 2006;33(1):6469.
Concepción-Zavaleta, Marcio, et al. "Factores de riesgo asociados a mortalidad en pacientes con enfermedad renal crónica terminal." Rev Soc Peru Med Interna 28.2 (2015): 72-8.
de Mutsert, Renée, et al. "Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition." Journal of renal nutrition 19.2 (2009): 127-135.
Gonzalez-Bedat, María Carlota, Guillermo Rosa-Diez, and Alejandro Ferreiro. "El Registro Latinoamericano de Diálisis y Trasplante Renal: la importancia del desarrollo de los registros nacionales en Latinoamérica." Nefrología Latinoamericana 14.1 (2017): 12-21.
Evans, Philip D., and Maarten W. Taal. "Epidemiology and causes of chronic kidney disease." Medicine 39.7 (2011): 402-406.
Rivillas, Juan C., et al. "Envejecimiento poblacional y desigualdades sociales en la mortalidad del adulto mayor en Colombia¿ Por qué abordarlos ahora y dónde comenzar?." Facultad Nacional de Salud Pública: El escenario para la salud pública desde la ciencia 35.3 (2017): 10.
Weng, Cheng-Hao, et al. "Nutritional predictors of mortality in long term hemodialysis patients." Scientific reports 6 (2016): 35639.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
World Kidney Day 2015; http://www.worldkidneyday.org/faqs/chronic-kidney-disease/.
Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. Jul 20 2013;382(9888):260-272.
Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. Dec 2011;80(12):1258-1270.
Connor A, Lillywhite R, Cooke MW. The carbon footprints of home and in-center maintenance hemodialysis in the United Kingdom. Hemodial Int. 2011 Jan;15(1):39-51. doi: 10.1111/j.1542-4758.2010.00523. x. Epub 2011 Jan 14
Daugirdas JT. Bases fisiológicas y modelo cinético de la urea. Manual de diálisis. 4ta ed. Madrid: Lippincott and Wilkins; 2007.
Nissenson AR, Fine RN. Modelo cinético de la urea como guía terapéutica de hemodiálisis en adultos. Manual de diálisis. 4ta ed. Madrid: Elsevier Masson; 2008.
Ward AR, Idoux WJ, Ouseph R, Depner T, Golper T. Dialysate flow rate and delivered Kt/V urea fordialyzers with enhanced dialysate flow distribution. Clinical J SocNeph 2011; 6: 2235-9.
Ouseph R, Ward AR. Increasing dialysate flow rate increases dialyzer urea mass transfer-area coefficients during clinical use. Am J Kidney Dis 2001; 37 (2): 316-20.
Bhimani JP, Ouseph R, Ward RA. Effect of increasing dialysate flow rate on diffusive mass transfer of urea, phosphate and β2-microglobulin during clinical haemodialysis. Nephrol Dial Transplant 2010; 25 (12): 3990-5.
Leypoldt J, Craig D. Kamerath, Janice F. Gilson, And Goetz Friederichs Dialyzer Clearances and Mass Transfer-Area Coefficients for Small Solutes at Low Dialysate Flow Rates, ASAIO Journal 2007 DOI: 10.1097/01.mat.0000245525.83936.79
Asar AT. Increasing dialysate flow rate increases dyalizer urea clearence and dialysis efficiency: an in vivo study. Saudi J Kidney Dis Transpl 2009; 6 (20): 1023-9.
Alayoud A, Benyahia M, Montassir D, Hamzi A, Zajjari Y, Bahadi A, El Kabbaj D et al. A model to predict optimal dialysate flow. Therap Apheresis Dial 2012; 16 (2): 152-8.
Ducuara D, Molano A, Yunez A, Wancjer B, Effect of flow adjustment dialysate (Qd) hemodialysis on effectiveness of underweight patients, Revista Ciencias de la Salud 11(2):173-183 · August 2013
Ahrenholz P, Roland E. Winkler, Diego Zendeh-Zartochti The role of the dialysate flow rate in haemodialysisBioArt Products GmbH Rostock, 2: Praxis verbundDialyse und Apherese Rostock, September 2013 DOI: 10.5772/58878
Yamamoto K, Matsukawa H, Yakushiji T, Technical Evaluation of Dialysate Flow in a Newly Designed Dialyzer, ASAIO Journal 2007; 53:36-40.
Agar JWM, Simmonds RE, Knight R, Somerville CA. Using water wisely: New, affordable, and essential water conservation practices for facility and home hemodialysis. Hemodial Int. 2009;13(1):32-37. doi:10.1111/j.1542-4758.2009.00332.x.
World Health Organization. Guidelines for drinking-water quality: recommendations. Vol. 1. World Health Organization, 2004.
Agar JWM. Green Dialysis: The Environmental Challenges A head. Semin Dial. 2015;28(2):186-192. doi:10.1111/sdi.12324.
Sanabria M, Moreno J, Vesga J, Astudillo K, Bunch A, et al. Mortalidad observada versus esperada en una red de unidades de diálisis en Colombia. Acta Médica Colombiana 2017;42:106-111.
Otero GA, De Francisco A, Gayoso P, García F. Prevalencia de la insuficiencia renal crónica en España: Resultados del estudio EPIRCE. Nefrología. 2010;30(01):78-86.
Wagner M, et al. Predicting Mortality in Incident Dialysis Patients: An Analysis of the United Kingdom Renal Registry. Am J Kidney Dis. 2011;57(6):894-902.
Pérez-García, Rafael, et al. "Estudio epidemiológico de 7316 pacientes en hemodiálisis tratados en las clínicas Fresenius Medical Care de España, con los datos obtenidos mediante la base de datos EuCliD®: resultados de los años 2009-2010." Nefrología (Madrid) 32.6 (2012): 743-753.
Kashiwagi, Tetsuya, et al. "Effects of reduced dialysis fluid flow in hemodialysis." Journal of Nippon Medical School 80.2 (2013): 119-130.
Brattich M. Morbidity and mortality in patients on dialysis: the impact of hemoglobin levels. Nephrol Nursing J. 2006;33(1):6469.
Concepción-Zavaleta, Marcio, et al. "Factores de riesgo asociados a mortalidad en pacientes con enfermedad renal crónica terminal." Rev Soc Peru Med Interna 28.2 (2015): 72-8.
de Mutsert, Renée, et al. "Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition." Journal of renal nutrition 19.2 (2009): 127-135.
Gonzalez-Bedat, María Carlota, Guillermo Rosa-Diez, and Alejandro Ferreiro. "El Registro Latinoamericano de Diálisis y Trasplante Renal: la importancia del desarrollo de los registros nacionales en Latinoamérica." Nefrología Latinoamericana 14.1 (2017): 12-21.
Evans, Philip D., and Maarten W. Taal. "Epidemiology and causes of chronic kidney disease." Medicine 39.7 (2011): 402-406.
Rivillas, Juan C., et al. "Envejecimiento poblacional y desigualdades sociales en la mortalidad del adulto mayor en Colombia¿ Por qué abordarlos ahora y dónde comenzar?." Facultad Nacional de Salud Pública: El escenario para la salud pública desde la ciencia 35.3 (2017): 10.
Weng, Cheng-Hao, et al. "Nutritional predictors of mortality in long term hemodialysis patients." Scientific reports 6 (2016): 35639.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Antecedentes: La hemodiálisis requiere una gran cantidad de agua. Con el desarrollo de los nuevos filtros de alta eficiencia la depuración de moléculas depende en menor grado de la velocidad del líquido QD lo que permitiría prescribir menores ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63686d3bea7987348881f1b441cffeb
Publikováno v:
Camaschella C. Iron-Deficiency Anemia. New England Journal of Medicine. 2015;372(19):1832-43
Organización Mundial de la S. Concentraciones de hemoglobina para diagnosticar la anemia y evaluar su gravedad. Who/Nmh/Nhd/111. 2011:1-7
WHO. Worldwide prevalence of anaemia. WHO Report. 2005:51
Dolman HS, Evans K, Zimmerman LH, Lavery T, Baylor AE, Wilson RF, et al. Impact of minimizing diagnostic blood loss in the critically ill. Surgery. 2015;158(4):1083--8
Nutritional anaemias. Report of a WHO group of experts. 1972. p. 1--29
Kassebaum NJ. The Global Burden of Anemia. Hematology/Oncology Clinics of North America. 2016;30(2):247-308
Martin ND, Scantling D. Hospital-Acquired Anemia: A Contemporary Review of Etiologies and Prevention Strategies. Journal of infusion nursing : the official publication of the Infusion Nurses Society. 2015;38(5):330-8
Salisbury AC, Alexander KP, Reid KJ, Masoudi FA, Rathore SS, Wang TY, et al. Incidence, correlates, and outcomes of acute, hospital-acquired anemia in patients with acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2010;3(4):337-46
Ahmed AH. Prevention and management of hospital-acquired anemia. Hospital Medicine Clinics. 2014;3(1):e71--e84
Kosiborod M, Krumholz HM, Jones PG, Pitt B, Spertus JA. The relationship between anemia, change in hematocrit over time and change in health status in patients with heart failure after myocardial infarction. Journal of cardiac failure. 2008;14(1):27-34
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Organización Mundial de la S. Concentraciones de hemoglobina para diagnosticar la anemia y evaluar su gravedad. Who/Nmh/Nhd/111. 2011:1-7
WHO. Worldwide prevalence of anaemia. WHO Report. 2005:51
Dolman HS, Evans K, Zimmerman LH, Lavery T, Baylor AE, Wilson RF, et al. Impact of minimizing diagnostic blood loss in the critically ill. Surgery. 2015;158(4):1083--8
Nutritional anaemias. Report of a WHO group of experts. 1972. p. 1--29
Kassebaum NJ. The Global Burden of Anemia. Hematology/Oncology Clinics of North America. 2016;30(2):247-308
Martin ND, Scantling D. Hospital-Acquired Anemia: A Contemporary Review of Etiologies and Prevention Strategies. Journal of infusion nursing : the official publication of the Infusion Nurses Society. 2015;38(5):330-8
Salisbury AC, Alexander KP, Reid KJ, Masoudi FA, Rathore SS, Wang TY, et al. Incidence, correlates, and outcomes of acute, hospital-acquired anemia in patients with acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2010;3(4):337-46
Ahmed AH. Prevention and management of hospital-acquired anemia. Hospital Medicine Clinics. 2014;3(1):e71--e84
Kosiborod M, Krumholz HM, Jones PG, Pitt B, Spertus JA. The relationship between anemia, change in hematocrit over time and change in health status in patients with heart failure after myocardial infarction. Journal of cardiac failure. 2008;14(1):27-34
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: Diferentes avances médicos están conllevando al desarrollo de anemia intrahospitalaria. Empero, en pacientes médicos no se ha descrito el comportamiento ni los factores asociados. Diseño: Estudio observacional analítico, cohorte r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbc28c3a340e8258b4b7a937cb4f6b92
Autor:
Doria, Cesar, Cantillo, Wainer
Publikováno v:
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: La enfermedad renal crónica es un factor independiente de riesgo cardiovascular y a su vez la enfermedad coronaria es un predictor de mortalidad en la población en diálisis. Materiales y métodos: Cohorte histórica de pacientes may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f603ef9d79e727175b459899f8788349
http://repository.urosario.edu.co/handle/10336/14185
http://repository.urosario.edu.co/handle/10336/14185
Publikováno v:
Granata A, Clementi A, Virzi GM, Brocca A, de Cal M, Scarfia VR, et al. Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment. European journal of internal medicine. 2016.
Casado Cerrada J, Perez Calvo JI. [Organ damage and cardiorenal syndrome in acute heart failure]. Medicina clinica. 2014;142 Suppl 1:26-31.
Nunez J, Minana G, Santas E, Bertomeu-Gonzalez V. Cardiorenal Syndrome in Acute Heart Failure: Revisiting Paradigms. Revista espanola de cardiologia (English ed). 2015;68(5):426-35.
Pai P. Cardiorenal syndrome. Hong Kong Journal of Nephrology. 2015;17(2):36-45.
Adriaan A. Voors et al. 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal (2016) 37, 2129 – 2200.
Montenegro Jesus.Tratado de Dialisis Peritoneal. Elsevier España.2015.
I-Kuan Wang et al. Permanent Cardiac Pacing in patients with end-stage renal disease undergoing dialysis.Nephrol Dial Transplant; 31:2115-2122.
Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2010; 31:703-11.
Fonarow ;ADHERE Scientific Advisory Committee: The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; 4:S21–S30.
Schrier RW: Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006; 47: 1–8.
Renhua Lu. Peritoneal Dialysis in Patients with Refractory Congestive Heart Failure: A Systematic Review. Cardiorenal Med 2015;5: 145–156.
Adachi Y, Nakagawa Y, Nishio A. Icodextrine preserves residual renal function in patients treated with automated peritoneal dialysis.Perit Dial Int 2006; 26:405.
Uchino S, Doig GS, Bellomo R, et al. Diuretics and mortality in acute renal failure. Crit Care Med 2004; 32:1669-1677.
Hidaka H, Nakao T.Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis.Nephrology.2003 Aug;8(4):184-91
Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group (1994) Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 46:496–503
Smith GL, Shlipak MG, Havranek EP et al. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 2005; 111: 1270–1277.
Hanna Fröhlich. Peritoneal ultrafiltration in end-stage chronic heart failure. Clin Kidney J (2015) 8: 219–225
Constanzo MR, Saltzberg M, O'Sullivan J, et al. Early ultrafiltration in patients with descompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005; 46:2047-51.
Rajapakse NW, Nanayakkara S, Kaye DM. Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment. Pharmacology & therapeutics. 2015;154:1-12.
Scabbia EV, Scabbia L. The Cardio-renal Syndrome (CRS). IJC Metabolic & Endocrine. 2015;9:1-4.
Clementi A, Virzi GM, Brocca A, de Cal M, Pastori S, Clementi M, et al. Advances in the pathogenesis of cardiorenal syndrome type 3. Oxidative medicine and cellular longevity. 2015;2015:148082
Chuasuwan A, Kellum JA. Cardio-renal syndrome type 3: epidemiology, pathophysiology, and treatment. Seminars in nephrology. 2012;32(1):31-9.
Clementi A, Virzi GM, Goh CY, Cruz DN, Granata A, Vescovo G, et al. Cardiorenal syndrome type 4: a review. Cardiorenal medicine. 2013;3(1):63-70.
Clementi A, Virzi GM, Brocca A, de Cal M, Vescovo G, Granata A, et al. Cardiorenal syndrome type 4: management. Blood purification. 2013;36(3-4):200-9.
Brocca A, Virzi GM, Pasqualin C, Pastori S, Marcante S, de Cal M, et al. Cardiorenal syndrome type 5: in vitro cytotoxicity effects on renal tubular cells and inflammatory profile. Analytical cellular pathology (Amsterdam). 2015;2015:469461.
Giusto Viglino et al. Peritoneal ultrafiltration in congestive heart failure-findings reported from its application in clinical practice: a systematic review. J Nephrol (2015) 28:29–38.
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364:797-805.
Domansky M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42:705-708.
Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83.
Silvio V. Bertoli. Peritoneal ultrafiltration in refractory heart failure: a cohort study Cécile Courivaud, peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Peritoneal Dialysis International2014, Vol. 34, pp. 100–108.
Karlien Francois. Peritoneal Dialysis for Chronic Congestive Heart Failure. Blood Purif 2015; 40:45–52.
Jessup M et al.: 2009 focused update: ACCF/AHA Guidelines for the Diagnosis andManagement of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977–2016.
Fonarow;ADHERE Scientific Advisory Committee: The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; 4:S21–S30.
Eknoyan G, Beck GJ, Cheung AK, et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010e2019.
Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF,Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E. Ultrafiltration in decompensated heart 22 failure with cardiorenal syndrome. N Engl J Med 2012; 367: 2296-2304 [PMID:23131078 DOI: 10.1056/NEJMoa1210357]
Paniagua R, Amato D, Vonesh E, et al. Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307e1320.
Van Biesen W, Lameire N, Verbeke F, et al. Residual renal function and volume status in peritoneal dialysis patients: a conflict of interest? J Nephrol 2008; 21:299e304.
Amir kasory et al.Peritoneal dialysis for chronic cardiorenal syndrome: Lessons learned from ultrafiltration trials, World J Cardiol 2015 July 26; 7(7): 392-396.
Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Am Soc Hypertens 2009; 3 : 80e83.
Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11:556e564.
Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT; NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol. 2004; 15 (4):1061–1070.
Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure.J Am Coll Cardiol 2012;60:10314.
Cruz DN et al: Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 2013; 182: 117–136.
Morduchowicz G, Winkler J, Zabludowski JR, Boner G: Effects of residual function in haemodialysis patients. Int Urol Nephrol 26:125-31, 1994.
Giusto Viglino et al. Peritoneal ultrafiltration in congestive heart failure-findings reported from its application in clinical practice: a systematic review. J Nephrol (2015) 28:29–38
Borrego F, Selga R, de Álvaro F, Bajo MA et al. Seguimiento de la función renal residual en pacientes en DPCA. La influencia de los aclaramientos peritoneales y de los fármacos. Nefrología. 1993; 13(1):37-46
Wolfson M, Piraino B, Hamburger RJ et al (2002) A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 40:1055–1065
Altmann P, Butler KC, Flowman D: Residual renal function in hemodialysis patients may protect against hyperaluminemia. Kidney Int 32: 710-3, 1987.
Smith GL, Shlipak MG, Havranek EP et al. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 2005;111: 1270–1277.
Bergman JM, Thorpe KE, Churchill DN; CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 2001;12(10):2158–2162.
Holley JL, Aslam N, Bernardini J, Fried L, Piraino B. The influence of demographic factor and modality on loss of residual renal function in incident peritoneal dialysis patients. Peritoneal Dialysis International 2001 Perit Dial Int. 2001 May-Jun;21(3):302-5.
Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(Suppl.12):S16-S23.
Tian SL, Tian XK, Han QF, Axelsson J, Wang T. Presence of peripheral arterial disease predicts loss of residual renal function in incident CAPD patients Perit Dial Int. 2012 Jan-Feb;32(1):67-72.
Hung AM, Young BS, Chertow GM. The decline in residual renal function in hemodialysis is slow and age dependent. Hemodial Int. 2003 Jan 1;7(1):17-22.
Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997 Jun;51(6):1908-19
Cnossen TT, Kooman JP, Konings CJ, Uszko-Lencer NH, Leunissen KM, van der Sande FM. Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure. Blood Purif. 2010; 30(2):146-52.
Courivaud C, Kazory A, Crépin T, Azar R, Bresson-Vautrin C, Chalopin JM, Ducloux D. Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Perit Dial Int. 2014 Jan-Feb; 34(1):100-8
Liao CT, Chen YM, Shiao CC, Hu FC, Huang JW, Kao TW, et al. Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. Nephrol Dial Transplant 2009; 24:2909-14.
Sheppard R, Panyon J, Pohwani AL, Kapoor A, Macgowan G, McNamara D, Mathier M, Johnston JR, Murali S. Intermittent outpatient ultrafiltration for the treatment of severe refractory congestive heart failure. J Card Fail. 2004 Oct; 10(5):380-3.
Koch M, Haastert B, Kohnle M, Rump LC, Kelm M, Trapp R, Aker S. Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail. 2012 May; 14(5):530-9.
USRDS. Table H.29. Mortality rates by primary cause of mortality, unadjusted. In: USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the U.S. Bethesda, MD: National Institutes of Health: National Institute of Diabetes Digestive and Kidney Diseases; 2007: H.29.
Abilash Koratala, Ankur Jain. Ultrafiltration does provide more efficient decongestion compared to conventiona for acute heart failure.International Journal Of Cardiology; December 27, 2016.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Casado Cerrada J, Perez Calvo JI. [Organ damage and cardiorenal syndrome in acute heart failure]. Medicina clinica. 2014;142 Suppl 1:26-31.
Nunez J, Minana G, Santas E, Bertomeu-Gonzalez V. Cardiorenal Syndrome in Acute Heart Failure: Revisiting Paradigms. Revista espanola de cardiologia (English ed). 2015;68(5):426-35.
Pai P. Cardiorenal syndrome. Hong Kong Journal of Nephrology. 2015;17(2):36-45.
Adriaan A. Voors et al. 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal (2016) 37, 2129 – 2200.
Montenegro Jesus.Tratado de Dialisis Peritoneal. Elsevier España.2015.
I-Kuan Wang et al. Permanent Cardiac Pacing in patients with end-stage renal disease undergoing dialysis.Nephrol Dial Transplant; 31:2115-2122.
Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2010; 31:703-11.
Fonarow ;ADHERE Scientific Advisory Committee: The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; 4:S21–S30.
Schrier RW: Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006; 47: 1–8.
Renhua Lu. Peritoneal Dialysis in Patients with Refractory Congestive Heart Failure: A Systematic Review. Cardiorenal Med 2015;5: 145–156.
Adachi Y, Nakagawa Y, Nishio A. Icodextrine preserves residual renal function in patients treated with automated peritoneal dialysis.Perit Dial Int 2006; 26:405.
Uchino S, Doig GS, Bellomo R, et al. Diuretics and mortality in acute renal failure. Crit Care Med 2004; 32:1669-1677.
Hidaka H, Nakao T.Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis.Nephrology.2003 Aug;8(4):184-91
Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group (1994) Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 46:496–503
Smith GL, Shlipak MG, Havranek EP et al. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 2005; 111: 1270–1277.
Hanna Fröhlich. Peritoneal ultrafiltration in end-stage chronic heart failure. Clin Kidney J (2015) 8: 219–225
Constanzo MR, Saltzberg M, O'Sullivan J, et al. Early ultrafiltration in patients with descompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005; 46:2047-51.
Rajapakse NW, Nanayakkara S, Kaye DM. Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment. Pharmacology & therapeutics. 2015;154:1-12.
Scabbia EV, Scabbia L. The Cardio-renal Syndrome (CRS). IJC Metabolic & Endocrine. 2015;9:1-4.
Clementi A, Virzi GM, Brocca A, de Cal M, Pastori S, Clementi M, et al. Advances in the pathogenesis of cardiorenal syndrome type 3. Oxidative medicine and cellular longevity. 2015;2015:148082
Chuasuwan A, Kellum JA. Cardio-renal syndrome type 3: epidemiology, pathophysiology, and treatment. Seminars in nephrology. 2012;32(1):31-9.
Clementi A, Virzi GM, Goh CY, Cruz DN, Granata A, Vescovo G, et al. Cardiorenal syndrome type 4: a review. Cardiorenal medicine. 2013;3(1):63-70.
Clementi A, Virzi GM, Brocca A, de Cal M, Vescovo G, Granata A, et al. Cardiorenal syndrome type 4: management. Blood purification. 2013;36(3-4):200-9.
Brocca A, Virzi GM, Pasqualin C, Pastori S, Marcante S, de Cal M, et al. Cardiorenal syndrome type 5: in vitro cytotoxicity effects on renal tubular cells and inflammatory profile. Analytical cellular pathology (Amsterdam). 2015;2015:469461.
Giusto Viglino et al. Peritoneal ultrafiltration in congestive heart failure-findings reported from its application in clinical practice: a systematic review. J Nephrol (2015) 28:29–38.
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364:797-805.
Domansky M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42:705-708.
Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83.
Silvio V. Bertoli. Peritoneal ultrafiltration in refractory heart failure: a cohort study Cécile Courivaud, peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Peritoneal Dialysis International2014, Vol. 34, pp. 100–108.
Karlien Francois. Peritoneal Dialysis for Chronic Congestive Heart Failure. Blood Purif 2015; 40:45–52.
Jessup M et al.: 2009 focused update: ACCF/AHA Guidelines for the Diagnosis andManagement of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977–2016.
Fonarow;ADHERE Scientific Advisory Committee: The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; 4:S21–S30.
Eknoyan G, Beck GJ, Cheung AK, et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010e2019.
Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF,Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E. Ultrafiltration in decompensated heart 22 failure with cardiorenal syndrome. N Engl J Med 2012; 367: 2296-2304 [PMID:23131078 DOI: 10.1056/NEJMoa1210357]
Paniagua R, Amato D, Vonesh E, et al. Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307e1320.
Van Biesen W, Lameire N, Verbeke F, et al. Residual renal function and volume status in peritoneal dialysis patients: a conflict of interest? J Nephrol 2008; 21:299e304.
Amir kasory et al.Peritoneal dialysis for chronic cardiorenal syndrome: Lessons learned from ultrafiltration trials, World J Cardiol 2015 July 26; 7(7): 392-396.
Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Am Soc Hypertens 2009; 3 : 80e83.
Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11:556e564.
Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT; NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol. 2004; 15 (4):1061–1070.
Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure.J Am Coll Cardiol 2012;60:10314.
Cruz DN et al: Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 2013; 182: 117–136.
Morduchowicz G, Winkler J, Zabludowski JR, Boner G: Effects of residual function in haemodialysis patients. Int Urol Nephrol 26:125-31, 1994.
Giusto Viglino et al. Peritoneal ultrafiltration in congestive heart failure-findings reported from its application in clinical practice: a systematic review. J Nephrol (2015) 28:29–38
Borrego F, Selga R, de Álvaro F, Bajo MA et al. Seguimiento de la función renal residual en pacientes en DPCA. La influencia de los aclaramientos peritoneales y de los fármacos. Nefrología. 1993; 13(1):37-46
Wolfson M, Piraino B, Hamburger RJ et al (2002) A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 40:1055–1065
Altmann P, Butler KC, Flowman D: Residual renal function in hemodialysis patients may protect against hyperaluminemia. Kidney Int 32: 710-3, 1987.
Smith GL, Shlipak MG, Havranek EP et al. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 2005;111: 1270–1277.
Bergman JM, Thorpe KE, Churchill DN; CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 2001;12(10):2158–2162.
Holley JL, Aslam N, Bernardini J, Fried L, Piraino B. The influence of demographic factor and modality on loss of residual renal function in incident peritoneal dialysis patients. Peritoneal Dialysis International 2001 Perit Dial Int. 2001 May-Jun;21(3):302-5.
Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(Suppl.12):S16-S23.
Tian SL, Tian XK, Han QF, Axelsson J, Wang T. Presence of peripheral arterial disease predicts loss of residual renal function in incident CAPD patients Perit Dial Int. 2012 Jan-Feb;32(1):67-72.
Hung AM, Young BS, Chertow GM. The decline in residual renal function in hemodialysis is slow and age dependent. Hemodial Int. 2003 Jan 1;7(1):17-22.
Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997 Jun;51(6):1908-19
Cnossen TT, Kooman JP, Konings CJ, Uszko-Lencer NH, Leunissen KM, van der Sande FM. Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure. Blood Purif. 2010; 30(2):146-52.
Courivaud C, Kazory A, Crépin T, Azar R, Bresson-Vautrin C, Chalopin JM, Ducloux D. Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Perit Dial Int. 2014 Jan-Feb; 34(1):100-8
Liao CT, Chen YM, Shiao CC, Hu FC, Huang JW, Kao TW, et al. Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. Nephrol Dial Transplant 2009; 24:2909-14.
Sheppard R, Panyon J, Pohwani AL, Kapoor A, Macgowan G, McNamara D, Mathier M, Johnston JR, Murali S. Intermittent outpatient ultrafiltration for the treatment of severe refractory congestive heart failure. J Card Fail. 2004 Oct; 10(5):380-3.
Koch M, Haastert B, Kohnle M, Rump LC, Kelm M, Trapp R, Aker S. Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail. 2012 May; 14(5):530-9.
USRDS. Table H.29. Mortality rates by primary cause of mortality, unadjusted. In: USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the U.S. Bethesda, MD: National Institutes of Health: National Institute of Diabetes Digestive and Kidney Diseases; 2007: H.29.
Abilash Koratala, Ankur Jain. Ultrafiltration does provide more efficient decongestion compared to conventiona for acute heart failure.International Journal Of Cardiology; December 27, 2016.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: La ICC que deteriora la función renal es denominada SCR. La DP se plantea como alternativa que impacta en la función cardíaca, hospitalización, síntomas e incluso en la mortalidad 3-5 . Objetivo: Describir el comportamiento de la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7259fe3034ba9a787e748f194c8e32a8
Publikováno v:
Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Annals of Internal Medicine. 2003. p. 338–46.
Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet. 2001;68(1):14–25
Bishop DF, Kornreich R, Desnick RJ. Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3’ untranslated region. Proc Natl Acad Sci U S A. 1988;85(11):3903–7.
Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. Journal of medical genetics. 1996. p. 682–8.
Hasholt L, Sørensen SA, Wandall A, Andersen EB, Arlien-Søborg P. A Fabry’s disease heterozygote with a new mutation: biochemical, ultrastructural, and clinical investigations. Journal of medical genetics. 1990. p. 303–6.
Pabico RC, Atancio BC, McKenna BA, Pamukcoglu T, Yodaiken R. Renal pathologic lesions and functional alterations in a man with Fabry’s disease. Am J Med. 1973;55(3):415–25.
Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation. 1976. p. 818–25.
Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54.
Siamopoulos KC. Fabry disease: Kidney involvement and enzyme replacement therapy. Kidney International. 2004. p. 744–53.
Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. The New England journal of medicine. 1967.
Kornreich R, Desnick RJ, Bishop DF. Nucleotide sequence of the human alpha-galactosidase A gene. Nucleic Acids Res. 1989;17(8):3301–2.
Krawczak M, Ball E V, Fenton I, Stenson PD, Abeysinghe S, Thomas N, et al. Human gene mutation database-a biomedical information and research resource. Hum Mutat. 2000;15(1):45–51.
Dawson G, Sweeley CC. In vivo studies on glycosphingolipid metabolism in porcine blood. J Biol Chem. 1970;245(2):410–6.
Menkes DL. Images in neurology. The cutaneous stigmata of Fabry disease: an X-linked phakomatosis associated with central and peripheral nervous system dysfunction. Archives of neurology. 1999. p. 487.
Morgan SH, Rudge P, Smith SJ, Bronstein AM, Kendall BE, Holly E, et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)--investigation of symptomatic and presymptomatic patients. Q J Med. 1990;75(277):491–507.
Menkes DL, O’Neil TJ, Saenz KK. Fabry’s disease presenting as syncope, angiokeratomas, and spoke-like cataracts in a young man: discussion of the differential diagnosis. Military medicine. 1997. p. 773–6.
Onishi A, Dyck PJ. Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns. Arch Neurol. 1974;31(2):120–7.
Cable WJ, Kolodny EH, Adams RD. Fabry disease: impaired autonomic function. Neurology. 1982;32(5):498–502.
Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry’s disease. Arch Ophthalmol. 1979;97(4):671–6.
Sheth KJ, Werlin SL, Freeman ME, Hodach AE. Gastrointestinal structure and function in Fabry’s disease. Am J Gastroenterol. 1981;76(3):246–51.
Kampmann C, Baehner F, Ries M, Beck M. Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol. 2002;13 Suppl 2:S147–9.
Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudová J, Karetová D, et al. New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J. 2000;139(6):1101–8.
Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105(12):1407–11.
Mehta J, Tuna N, Moller JH, Desnick RJ. Electrocardiographic and vectorcardiographic abnormalities in Fabry’s disease. Am Heart J. 1977;93(6):699–705.
Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry’s disease. J Am Coll Cardiol. 1986;7(5):1157–61.
Nagao Y, Nakashima H, Fukuhara Y, Shimmoto M, Oshima A, Ikari Y, et al. Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A. Clinical genetics. 1991. p. 233–7.
Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol. 1996;40(1):8–17.
Mendez MF, Stanley TM, Medel NM, Li Z, Tedesco DT. The vascular dementia of Fabry’s disease. Dementia and geriatric cognitive disorders. p. 252–7.
Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, et al. Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64(3):801–7.
Largent EA, Pearson SD. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases. Hastings Cent Rep. 2012;42(1):27–34.
Jonsen AR. Bentham in a box: technology assessment and health care allocation. Law Med Health Care. 1986;14(3-4):172–4.
Waldek S, Feriozzi S. Fabry nephropathy: a review-how can we optimize the management of Fabry nephropathy? BMC Nephrol [Internet]. 2014;15(1):72. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4029839&tool=pmcentrez&rendertype=abstract
Romão EA, Lourenço CM, Júnior WM, Rolfs A, Muñoz V, Neto OMV, et al. What lies beneath: Fabry nephropathy in a female patient with severe cerebrovascular disease. Clinical Nephrology. 2012.
Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30(2):184–92.
Ardila Cardenas Maria Elizabeth MS. Prevalencia de la enfermedad de Fabry en hombres con Insuficiencia Renal Cronica en Unidades Renales de RTS Colombia. Cat Univ del Rosario. 2008
Kalkan Uçar S, Sozmen E, Duman S, Başçi A, Çoker M. Alpha-Galactosidase A Activity Levels in Turkish Male Hemodialysis Patients. Ther Apher Dial. 2012;16(6):560–5.
Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, et al. Fabry nephropathy: Indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrology Dialysis Transplantation. 2013. p. 505–17.
“Rare Diseases: understanding this Public Health Priority” [Internet]. Understanding this Public Health Priority-Eurordis. 2005. Available from: www.eurordis.org/IMG/.../princeps_document-EN.p...
Goolsby MJ. National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification. J Am Acad Nurse Pract. 2002;14(6):238–42.
Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD. Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Qual Life Res. 2002;11(2):127–33.
Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, et al. Newborn screening for fabry disease in taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat. 2009;30(10):1397–405.
Maixnerová D, Tesař V, Ryšavá R, Reiterová J, Poupětová H, Dvořáková L, et al. The coincidence of IgA nephropathy and Fabry disease. BMC Nephrol [Internet]. 2013;14:6. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3549770&tool=pmcentrez&rendertype=abstract
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet. 2001;68(1):14–25
Bishop DF, Kornreich R, Desnick RJ. Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3’ untranslated region. Proc Natl Acad Sci U S A. 1988;85(11):3903–7.
Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. Journal of medical genetics. 1996. p. 682–8.
Hasholt L, Sørensen SA, Wandall A, Andersen EB, Arlien-Søborg P. A Fabry’s disease heterozygote with a new mutation: biochemical, ultrastructural, and clinical investigations. Journal of medical genetics. 1990. p. 303–6.
Pabico RC, Atancio BC, McKenna BA, Pamukcoglu T, Yodaiken R. Renal pathologic lesions and functional alterations in a man with Fabry’s disease. Am J Med. 1973;55(3):415–25.
Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation. 1976. p. 818–25.
Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54.
Siamopoulos KC. Fabry disease: Kidney involvement and enzyme replacement therapy. Kidney International. 2004. p. 744–53.
Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. The New England journal of medicine. 1967.
Kornreich R, Desnick RJ, Bishop DF. Nucleotide sequence of the human alpha-galactosidase A gene. Nucleic Acids Res. 1989;17(8):3301–2.
Krawczak M, Ball E V, Fenton I, Stenson PD, Abeysinghe S, Thomas N, et al. Human gene mutation database-a biomedical information and research resource. Hum Mutat. 2000;15(1):45–51.
Dawson G, Sweeley CC. In vivo studies on glycosphingolipid metabolism in porcine blood. J Biol Chem. 1970;245(2):410–6.
Menkes DL. Images in neurology. The cutaneous stigmata of Fabry disease: an X-linked phakomatosis associated with central and peripheral nervous system dysfunction. Archives of neurology. 1999. p. 487.
Morgan SH, Rudge P, Smith SJ, Bronstein AM, Kendall BE, Holly E, et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)--investigation of symptomatic and presymptomatic patients. Q J Med. 1990;75(277):491–507.
Menkes DL, O’Neil TJ, Saenz KK. Fabry’s disease presenting as syncope, angiokeratomas, and spoke-like cataracts in a young man: discussion of the differential diagnosis. Military medicine. 1997. p. 773–6.
Onishi A, Dyck PJ. Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns. Arch Neurol. 1974;31(2):120–7.
Cable WJ, Kolodny EH, Adams RD. Fabry disease: impaired autonomic function. Neurology. 1982;32(5):498–502.
Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry’s disease. Arch Ophthalmol. 1979;97(4):671–6.
Sheth KJ, Werlin SL, Freeman ME, Hodach AE. Gastrointestinal structure and function in Fabry’s disease. Am J Gastroenterol. 1981;76(3):246–51.
Kampmann C, Baehner F, Ries M, Beck M. Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol. 2002;13 Suppl 2:S147–9.
Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudová J, Karetová D, et al. New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J. 2000;139(6):1101–8.
Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105(12):1407–11.
Mehta J, Tuna N, Moller JH, Desnick RJ. Electrocardiographic and vectorcardiographic abnormalities in Fabry’s disease. Am Heart J. 1977;93(6):699–705.
Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry’s disease. J Am Coll Cardiol. 1986;7(5):1157–61.
Nagao Y, Nakashima H, Fukuhara Y, Shimmoto M, Oshima A, Ikari Y, et al. Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A. Clinical genetics. 1991. p. 233–7.
Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol. 1996;40(1):8–17.
Mendez MF, Stanley TM, Medel NM, Li Z, Tedesco DT. The vascular dementia of Fabry’s disease. Dementia and geriatric cognitive disorders. p. 252–7.
Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, et al. Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64(3):801–7.
Largent EA, Pearson SD. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases. Hastings Cent Rep. 2012;42(1):27–34.
Jonsen AR. Bentham in a box: technology assessment and health care allocation. Law Med Health Care. 1986;14(3-4):172–4.
Waldek S, Feriozzi S. Fabry nephropathy: a review-how can we optimize the management of Fabry nephropathy? BMC Nephrol [Internet]. 2014;15(1):72. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4029839&tool=pmcentrez&rendertype=abstract
Romão EA, Lourenço CM, Júnior WM, Rolfs A, Muñoz V, Neto OMV, et al. What lies beneath: Fabry nephropathy in a female patient with severe cerebrovascular disease. Clinical Nephrology. 2012.
Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30(2):184–92.
Ardila Cardenas Maria Elizabeth MS. Prevalencia de la enfermedad de Fabry en hombres con Insuficiencia Renal Cronica en Unidades Renales de RTS Colombia. Cat Univ del Rosario. 2008
Kalkan Uçar S, Sozmen E, Duman S, Başçi A, Çoker M. Alpha-Galactosidase A Activity Levels in Turkish Male Hemodialysis Patients. Ther Apher Dial. 2012;16(6):560–5.
Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, et al. Fabry nephropathy: Indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrology Dialysis Transplantation. 2013. p. 505–17.
“Rare Diseases: understanding this Public Health Priority” [Internet]. Understanding this Public Health Priority-Eurordis. 2005. Available from: www.eurordis.org/IMG/.../princeps_document-EN.p...
Goolsby MJ. National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification. J Am Acad Nurse Pract. 2002;14(6):238–42.
Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD. Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Qual Life Res. 2002;11(2):127–33.
Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, et al. Newborn screening for fabry disease in taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat. 2009;30(10):1397–405.
Maixnerová D, Tesař V, Ryšavá R, Reiterová J, Poupětová H, Dvořáková L, et al. The coincidence of IgA nephropathy and Fabry disease. BMC Nephrol [Internet]. 2013;14:6. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3549770&tool=pmcentrez&rendertype=abstract
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: La Enfermedad de Fabry (EF), es una enfermedad multisistémica de almacenamiento lisosomal ligada al cromosoma X que afecta principalmente a hombres, pero también puede causar significativa morbilidad en las mujeres heterocigotas (1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce9a170727e9f54e9747f8188bacadff
Publikováno v:
1. Penne E. Sodium Gradient : A tool to individualize dialysate sodium prescription in chronic Hemodialysis patients ? Blood Purif 2011; 31: 86-91.
2. Barth C, Boer W, Garzoni D, et al. Characteristics of hypotension-prone haemodialysis patients: is there a critical relative blood volume? Nephrol Dial Transplant 2003;18(7): 1353-1360.
3. Manlucu J. Lowering Postdialysis Plasma Sodium (Conductivity) to Increase Sodium Removal in Volume-Expanded Hemodialysis Patients: A Pilot Study Using a biofeedback Software System. American Journal of Kidney Diseases 2011;56 : 69-76.
4. Flanigan M. Dialysate composition and hemodialysis hypertension. Semin Dial 2004;17:279–283.
5. Charra B, Chazot C, Jean G et al. Role of sodium in dialysis. Minerva Urol Nefrol 2004; 56: 205–213.
6. Shaldon S. Dietary salt restriction and drug free treatment of hypertension in ESRD patients: a largely abandoned therapy. Nephrol Dial Transplant 2002; 17: 1163–1165.
7. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (5 Suppl. 3) S112–S119.
8. Kalantar-Zadeh K, Regidor DL, Kovesdy CP et al. Fluid retention is associated with cardiovascular mortality in patients undergoing longterm hemodialysis. Circulation 2009; 119: 671–679.
9. Munoz J, Sun, S. Dialysate sodium and sodium gradient in maintenance hemodialysis: a neglected sodium restriction approach?. Nephrol Dial Transplant (2011) 26: 1281 – 1287.
11. Keen ML, Gotch FA. The association of the sodium “setpoint” to interdialytic weight gain and blood pressure in hemodialysis patients. Int J Artif Organs 2007; 30: 971–979
12. Locatelli F. Dry weight and sodium balance. Semin Nephrol 2001; 21: 291-297.
13. Gotch FA. Preliminary clinic results with sodium-volume modeling of hemodialysis therapy. Proc Clin Dial Trasplant Forum 1980; 10:12-17.
14. Levin A. The benefits and side effects of ramped hypertonic sodium dialysis. J Am Soc Nephrol 1996;7:242-246.
15. Oliver MJ. Impact of sodium and ultrafiltration profiling on hemodialysis related-symptoms. J Am Soc Nephrol 2001;12:151-156.
16. Basile C. Efficacy and safety of haemodialysis treatment with the Hemocontrol TM biofeedback system. Nephrol Dial Transplant 2001;16:328-334.
17. Petitclerc T. A model for non invasive stimation of in vivo dialyzer performances and patient’s conductivity during hemodialysis. Int J Artif Organs 1993;16:585-591
18. Locatelli F. The effect on line conductivity plasma ultrafiltrate kinetic modeling on cardiovascular stability of hemodialysis patients. Kidney Inter 1998;53:1052-1060
19. Locatelli F. Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrol Dial Transplant 2004;19:785-796
20. Thein H. Associations of a facility level decrease in dialysate sodium concentration with blood pressure and interdialytic weight gain. Nephrol Dial Transplant 2007;22:2630-2639.
21. De Paula F. Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients. Kidney Int 2004;66:1232-1238.
22. Sun, S. Dialysate sodium and sodium gradient in maintenance hemodialysis. Nephrol Dial Transplant (2011) 26: 1281 – 1286.
23. Alayoud A. A model to predict optimal dialysate flow. Therapeutic Apheresis and Dialysis 2012;2:1-7.
24. Agar J, Simonds R. Using water wisely: new, affordable, and essential water conservation practices for facility and home hemodialysis. Hemodialysis Int. 2009; 13: 32 – 37.
25. Abramson J. Winpepi Programs PAIRSetc manual. Version 3.15. p 48. 2012
26. Ducuara D., Martínez A. Efecto de ajuste del flujo dializante (Qd) sobre la eficacia en hemodialisis a pacientes de bajo peso. Repositorio Universidad del Rosario. 2011
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
2. Barth C, Boer W, Garzoni D, et al. Characteristics of hypotension-prone haemodialysis patients: is there a critical relative blood volume? Nephrol Dial Transplant 2003;18(7): 1353-1360.
3. Manlucu J. Lowering Postdialysis Plasma Sodium (Conductivity) to Increase Sodium Removal in Volume-Expanded Hemodialysis Patients: A Pilot Study Using a biofeedback Software System. American Journal of Kidney Diseases 2011;56 : 69-76.
4. Flanigan M. Dialysate composition and hemodialysis hypertension. Semin Dial 2004;17:279–283.
5. Charra B, Chazot C, Jean G et al. Role of sodium in dialysis. Minerva Urol Nefrol 2004; 56: 205–213.
6. Shaldon S. Dietary salt restriction and drug free treatment of hypertension in ESRD patients: a largely abandoned therapy. Nephrol Dial Transplant 2002; 17: 1163–1165.
7. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (5 Suppl. 3) S112–S119.
8. Kalantar-Zadeh K, Regidor DL, Kovesdy CP et al. Fluid retention is associated with cardiovascular mortality in patients undergoing longterm hemodialysis. Circulation 2009; 119: 671–679.
9. Munoz J, Sun, S. Dialysate sodium and sodium gradient in maintenance hemodialysis: a neglected sodium restriction approach?. Nephrol Dial Transplant (2011) 26: 1281 – 1287.
11. Keen ML, Gotch FA. The association of the sodium “setpoint” to interdialytic weight gain and blood pressure in hemodialysis patients. Int J Artif Organs 2007; 30: 971–979
12. Locatelli F. Dry weight and sodium balance. Semin Nephrol 2001; 21: 291-297.
13. Gotch FA. Preliminary clinic results with sodium-volume modeling of hemodialysis therapy. Proc Clin Dial Trasplant Forum 1980; 10:12-17.
14. Levin A. The benefits and side effects of ramped hypertonic sodium dialysis. J Am Soc Nephrol 1996;7:242-246.
15. Oliver MJ. Impact of sodium and ultrafiltration profiling on hemodialysis related-symptoms. J Am Soc Nephrol 2001;12:151-156.
16. Basile C. Efficacy and safety of haemodialysis treatment with the Hemocontrol TM biofeedback system. Nephrol Dial Transplant 2001;16:328-334.
17. Petitclerc T. A model for non invasive stimation of in vivo dialyzer performances and patient’s conductivity during hemodialysis. Int J Artif Organs 1993;16:585-591
18. Locatelli F. The effect on line conductivity plasma ultrafiltrate kinetic modeling on cardiovascular stability of hemodialysis patients. Kidney Inter 1998;53:1052-1060
19. Locatelli F. Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrol Dial Transplant 2004;19:785-796
20. Thein H. Associations of a facility level decrease in dialysate sodium concentration with blood pressure and interdialytic weight gain. Nephrol Dial Transplant 2007;22:2630-2639.
21. De Paula F. Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients. Kidney Int 2004;66:1232-1238.
22. Sun, S. Dialysate sodium and sodium gradient in maintenance hemodialysis. Nephrol Dial Transplant (2011) 26: 1281 – 1286.
23. Alayoud A. A model to predict optimal dialysate flow. Therapeutic Apheresis and Dialysis 2012;2:1-7.
24. Agar J, Simonds R. Using water wisely: new, affordable, and essential water conservation practices for facility and home hemodialysis. Hemodialysis Int. 2009; 13: 32 – 37.
25. Abramson J. Winpepi Programs PAIRSetc manual. Version 3.15. p 48. 2012
26. Ducuara D., Martínez A. Efecto de ajuste del flujo dializante (Qd) sobre la eficacia en hemodialisis a pacientes de bajo peso. Repositorio Universidad del Rosario. 2011
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Objetivos: Determinar si existe diferencia en la ganancia interdialítica entre los pacientes al ser tratados con flujo de dializado (Qd) de 400 mL/min y 500 mL/min. Diseño: Se realizó un estudio de intervención, cruzado, aleatorizado, doble ciego
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4ff6afe9b0e166dfcee557780f18434
Publikováno v:
1. Jhon T Daugirdas, bases fisiológicas y Modelo Cinético de la urea, Manual de diálisis, 4ta edición, Lippincott 2007
2. Allen R Nissenson and Richard N Fine, Modelo Cinético de la Urea como Guía terapéutica de hemodiálisis en adultos, Manual de Diálisis, 4ta edición, Elsevier Masson, 2008
3. Ward A Richard, Idoux W John et al, Clinical Journal of the American Society of Nephrology, dialysate flow rate and delivered kt/vurea for dialyzers with enhanced dialysate flow distribution, vol 6 September, 2011
4. Rosemary Ouseph, Ward A Richard, Increasing Dialysate Flow Rate Increases Dialyzer Urea Mass Transfer-Area Coefficients during Clinical Use, American Journal of Kidney Diseases-Volume 37, Issue 2 (February 2001)
5. Ahmad Taher Asar, Saudi J Kidney Dis Transpl 2009; Increasing dyalisate Flow Rate Increases Dyalizer Urea Clearence and Dialysis Efficiency: an in Vivo Study, (20) 6:1023-1029
6. V . Barrio. Epidemiología de la insuficiencia renal terminal en tratamiento sustitutivo con diálisis en el anciano. Nefrología. vol. XVIII. Suplemento 4. 1998
7. P. Kimmel, M. Varela. Interdialytic weight gain and survival in hemodialysis Patients: Effects of duration of ESRD and diabetes mellitus. Kidney International, Vol. 57 (2000), pp. 1141–1151
8. G. Eknoyan, M.D., G. Beck Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis. N Engl J Med 2002; 347:2010-2019
9. KDOQI Guidelines 2006.
11. J. Mendoza, S. Sun, Dialysate sodium and sodium gradient in maintenance Hemodialysis: a neglected sodium restriction approach?. Nephrol Dial Transplant (2011) 26: 1281–1287
12. J. Gómez, M. Villaverde. Interdialytic weight gain as a marker of blood pressure, nutrition, and survival in hemodialysis patients. Kidney International, Vol. 67, Supplement 93 (2005), pp. S63–S68
13. S. Santos, A. Peixoto, Revisiting the Dialysate Sodium Prescription as a Tool for Better Blood Pressure and Interdialytic Weight Gain Management in Hemodialysis Patients. Clin J Am Soc Nephrol 3: 522–530, 2008
14. J. Leypoldt, A. Cheung. Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. Kidney International, Vol. 51 (1997), pp. 2013-2017
15. F. Maduell, H. García. Influencia del flujo del líquido de diálisis y de la hemodiafiltración sobre la eficacia de la diálisis. NEFROLOGIA. Vol. XVI. Núm. 4. 1996
16. F. Locatelli et al, optimal composition of the dialysate, with emphasis on its influence on blood pressure, Nephrol Dial Transplant (2004)19: 785-796
17. Alayoud A, Benyahia M, Montasir D, et al. A Model to Predict Optimal Dialysate Flow, Therapeutic Apheresis and Dialysis, Vol 2 2012
18. Blanco Restrepo J, maya Mejía JM, et al, Consideraciones éticas en investigación, Epidemiologia básica y principios de investigación, Segunda Edición, pag 241-249, 2006
19. Jai P. Bhimani, Rosemary Ouseph and Richard A. Ward, Nephrol Dial Transplant (2010), Effect of increasing dialysate flow rate on diffusive mass transfer of urea, phosphate and β2-microglobulin during clinical haemodialysis,25: 3990–3995
20. Portafolio, Fin de semana, El agua barata se está agotando, Foro mundial del agua ; Marsella, Francia, 17 a 19 de marzo 2012.
21. Cuenta de alto costo, Fondo colombiano de enfermedades de alto costo, Enfermedad renal crónica en Colombia 2010, Bogotá D.C, Noviembre 2011.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
2. Allen R Nissenson and Richard N Fine, Modelo Cinético de la Urea como Guía terapéutica de hemodiálisis en adultos, Manual de Diálisis, 4ta edición, Elsevier Masson, 2008
3. Ward A Richard, Idoux W John et al, Clinical Journal of the American Society of Nephrology, dialysate flow rate and delivered kt/vurea for dialyzers with enhanced dialysate flow distribution, vol 6 September, 2011
4. Rosemary Ouseph, Ward A Richard, Increasing Dialysate Flow Rate Increases Dialyzer Urea Mass Transfer-Area Coefficients during Clinical Use, American Journal of Kidney Diseases-Volume 37, Issue 2 (February 2001)
5. Ahmad Taher Asar, Saudi J Kidney Dis Transpl 2009; Increasing dyalisate Flow Rate Increases Dyalizer Urea Clearence and Dialysis Efficiency: an in Vivo Study, (20) 6:1023-1029
6. V . Barrio. Epidemiología de la insuficiencia renal terminal en tratamiento sustitutivo con diálisis en el anciano. Nefrología. vol. XVIII. Suplemento 4. 1998
7. P. Kimmel, M. Varela. Interdialytic weight gain and survival in hemodialysis Patients: Effects of duration of ESRD and diabetes mellitus. Kidney International, Vol. 57 (2000), pp. 1141–1151
8. G. Eknoyan, M.D., G. Beck Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis. N Engl J Med 2002; 347:2010-2019
9. KDOQI Guidelines 2006.
11. J. Mendoza, S. Sun, Dialysate sodium and sodium gradient in maintenance Hemodialysis: a neglected sodium restriction approach?. Nephrol Dial Transplant (2011) 26: 1281–1287
12. J. Gómez, M. Villaverde. Interdialytic weight gain as a marker of blood pressure, nutrition, and survival in hemodialysis patients. Kidney International, Vol. 67, Supplement 93 (2005), pp. S63–S68
13. S. Santos, A. Peixoto, Revisiting the Dialysate Sodium Prescription as a Tool for Better Blood Pressure and Interdialytic Weight Gain Management in Hemodialysis Patients. Clin J Am Soc Nephrol 3: 522–530, 2008
14. J. Leypoldt, A. Cheung. Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. Kidney International, Vol. 51 (1997), pp. 2013-2017
15. F. Maduell, H. García. Influencia del flujo del líquido de diálisis y de la hemodiafiltración sobre la eficacia de la diálisis. NEFROLOGIA. Vol. XVI. Núm. 4. 1996
16. F. Locatelli et al, optimal composition of the dialysate, with emphasis on its influence on blood pressure, Nephrol Dial Transplant (2004)19: 785-796
17. Alayoud A, Benyahia M, Montasir D, et al. A Model to Predict Optimal Dialysate Flow, Therapeutic Apheresis and Dialysis, Vol 2 2012
18. Blanco Restrepo J, maya Mejía JM, et al, Consideraciones éticas en investigación, Epidemiologia básica y principios de investigación, Segunda Edición, pag 241-249, 2006
19. Jai P. Bhimani, Rosemary Ouseph and Richard A. Ward, Nephrol Dial Transplant (2010), Effect of increasing dialysate flow rate on diffusive mass transfer of urea, phosphate and β2-microglobulin during clinical haemodialysis,25: 3990–3995
20. Portafolio, Fin de semana, El agua barata se está agotando, Foro mundial del agua ; Marsella, Francia, 17 a 19 de marzo 2012.
21. Cuenta de alto costo, Fondo colombiano de enfermedades de alto costo, Enfermedad renal crónica en Colombia 2010, Bogotá D.C, Noviembre 2011.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: Las guías KDOQI del 2006 utilizan patrón de adecuación de diálisis el Kt/V, donde V es volumen de distribución de la úrea, pacientes de bajo peso tienen menor agua corporal total, menor V, que podrían reducir el requerimiento de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bef107f0ae377055a686581441daea5b